Indacaterol

CHEMBL1095777 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
392.5 g/mol
LogP
3.3
Phase
4

This ultra-long-acting beta-2 agonist (LABA) bronchodilator is inhaled once daily for the maintenance treatment of COPD and asthma. It relaxes the smooth muscle surrounding the airways, improving airflow and reducing breathlessness throughout the day. It is used as a maintenance medication and does not provide rapid relief during an acute attack.

Molekularmasse

392,5000 g/mol

LogP

3,30

TPSA

81,60 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Wirkmechanismus

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2

InChI

InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1

Molecular Formula

C24H28N2O3

HBD / HBA

4 / 4

Rotierbare Bindungen

6

Schwere Atome

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

This ultra-long-acting beta-2 agonist (LABA) bronchodilator is inhaled once daily for the maintenance treatment of COPD and asthma. It relaxes the smooth muscle surrounding the airways, improving airflow and reducing breathlessness throughout the day. It is used as a maintenance medication and does not provide rapid relief during an acute attack.

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

Yes, Indacaterol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1095777. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6918554. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.